share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募资说明书
美股SEC公告 ·  05/09 11:22
Moomoo AI 已提取核心信息
Allarity Therapeutics Inc. has updated its prospectus supplement, initially filed on November 29, 2023, with a new supplement dated May 9, 2024. This latest filing amends the previous prospectus supplement from March 19, 2024, and relates to the company's At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The amendment follows an increase in Allarity Therapeutics' public float above $75 million as of May 2, 2024, which removes the previous sales limitation under Form S-3. Consequently, the company has revised the Sales Agreement to increase the total offering of common stock to $22 million, inclusive of the $19,633,424 in gross proceeds already raised through the sale of 14,982,765 shares prior to the amendment. The company cautions investors about the high degree of risk involved in investing in its common stock, as detailed in the risk factors section of the prospectus supplement dated March 19, 2024, and other referenced documents.
Allarity Therapeutics Inc. has updated its prospectus supplement, initially filed on November 29, 2023, with a new supplement dated May 9, 2024. This latest filing amends the previous prospectus supplement from March 19, 2024, and relates to the company's At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The amendment follows an increase in Allarity Therapeutics' public float above $75 million as of May 2, 2024, which removes the previous sales limitation under Form S-3. Consequently, the company has revised the Sales Agreement to increase the total offering of common stock to $22 million, inclusive of the $19,633,424 in gross proceeds already raised through the sale of 14,982,765 shares prior to the amendment. The company cautions investors about the high degree of risk involved in investing in its common stock, as detailed in the risk factors section of the prospectus supplement dated March 19, 2024, and other referenced documents.
Alarity Therapeutics Inc.已经更新了最初于2023年11月29日提交的招股说明书补充文件，新增的日期为2024年5月9日。这份最新文件修订了自2024年3月19日起的先前招股说明书补充文件，涉及该公司与Ascendiant Capital Markets, LLC签订的市场发行销售协议。该修正案是在截至2024年5月2日将Allarity Therapeutics的公众持股量增加到7500万美元以上之后发布的，这取消了先前在S-3表格下的销售限制。因此，该公司修订了销售协议，将普通股的发行总额增加到2200万美元，其中包括修订前通过出售14,982,765股已经筹集的19,633,424美元的总收益。该公司提醒投资者注意投资其普通股所涉及的高度风险，详见2024年3月19日招股说明书补充文件中的风险因素部分以及其他参考文件。
Alarity Therapeutics Inc.已经更新了最初于2023年11月29日提交的招股说明书补充文件，新增的日期为2024年5月9日。这份最新文件修订了自2024年3月19日起的先前招股说明书补充文件，涉及该公司与Ascendiant Capital Markets, LLC签订的市场发行销售协议。该修正案是在截至2024年5月2日将Allarity Therapeutics的公众持股量增加到7500万美元以上之后发布的，这取消了先前在S-3表格下的销售限制。因此，该公司修订了销售协议，将普通股的发行总额增加到2200万美元，其中包括修订前通过出售14,982,765股已经筹集的19,633,424美元的总收益。该公司提醒投资者注意投资其普通股所涉及的高度风险，详见2024年3月19日招股说明书补充文件中的风险因素部分以及其他参考文件。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息